- Abstract:
-
Alemtuzumab is a powerful lymphocyte depleting antibody currently being evaluated in solid organ transplantation. This paper describes 5-year results of a single center study of alemtuzumab as induction in renal transplantation. Thirty-three renal transplant recipients received 20 mg alemtuzumab on day 0 and 1, followed by half-dose cyclosporin monotherapy (trough concentration 75-125 ng/mL) from day 3. They were compared in a retrospective contemporaneous-controlled manner with 66 kidney tra...
Expand abstract - Publication status:
- Published
- Journal:
- American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
- Volume:
- 5
- Issue:
- 6
- Pages:
- 1347-1353
- Publication date:
- 2005-06-05
- DOI:
- EISSN:
-
1600-6143
- ISSN:
-
1600-6135
- URN:
-
uuid:5e291ad5-f0b5-48eb-a6f0-f90b5d785204
- Source identifiers:
-
6077
- Local pid:
- pubs:6077
- Language:
- English
- Keywords:
- Copyright date:
- 2005
Journal article
Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
Actions
Authors
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record